Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

macitentan

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

Gilead Sciences

Gilead receives FDA approval for PAH combo

Letairis with tadalafil given the nod for pulmonary arterial hypertension

- PMLiVE

Blue Latitude retains Janssen contract

Strategic marketing consultancy will continue tosupport the firm's EMEA brand teams

- PMLiVE

Janssen launches Stelara in the UK for adolescents

Psoriasis drug now available for younger patients

- PMLiVE

Imbruvica filed as first-line leukaemia therapy

Study shows improved progression-free survival

- PMLiVE

Taking a strategic approach

Janssen's Cyril Titeux on responding to the industry's pricing, access and reputational challenges

- PMLiVE

Janssen’s myeloma drug wins FDA priority review

Monotherapy daratumumab to be reviewed within six months

- PMLiVE

Gilead and GSK pulmonary hypertension drugs work in tandem

Letairis and Adcirca combined shows clear therapeutic benefit

- PMLiVE

J&J buys into Alligator’s immuno-oncology candidate

Will spend $700m on the early-stage cancer deal

Roche Basel Switzerland

Roche and AbbVie’s leukaemia drug set for filing by year-end

Blood cancer treatment venetoclax faces a tough market if approved

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Just manufacturing pills ‘no longer good enough for patients’

Pharma must truly move beyond the pill and embrace digital health, according to industry heads

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links